Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Olanzapine in Schizophrenia
NCT00100776Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of olanzapine in schizophrenia and schizoaffective disorder (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Fixed dose response relationship for efficacy. Started Sep 2003; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00100776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100776.